<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859246</url>
  </required_header>
  <id_info>
    <org_study_id>16-044H</org_study_id>
    <nct_id>NCT02859246</nct_id>
  </id_info>
  <brief_title>Mucinex® for Treatment of Filamentary Keratitis</brief_title>
  <official_title>Mucinex® for Treatment of Filamentary Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount
      of corneal filaments and improving symptomology in subjects with filamentary keratitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is aimed to determine if oral administration of Mucinex® is effective in reducing
      the amount of corneal filaments and improving symptomology in subjects with filamentary
      keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex®
      twice a day (total dose is 1.2 g/day) for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mucinex® for the treatment of filamentary keratitis</measure>
    <time_frame>1 month</time_frame>
    <description>Reduction of symptoms according to the ocular surface disease index score after treatment with oral Mucinex® twice a day for 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucinex® for the treatment of filamentary keratitis</measure>
    <time_frame>1 month</time_frame>
    <description>Reduction in the number of corneal filaments after treatment with oral Mucinex® twice a day for 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Filamentary Keratitis</condition>
  <arm_group>
    <arm_group_label>Mucinex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>600 mg of Mucinex 2 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucinex®</intervention_name>
    <description>Mucinex®</description>
    <arm_group_label>Mucinex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with filamentary keratitis

          -  18 years and older

        Exclusion Criteria:

          -  Active ocular surface infection of any type

          -  Recent ocular surgery (&lt;30 days) history of nephrolithiasis as Mucinex® has been
             associated in rare cases of development of kidney stones

          -  Schirmer's test&lt;3mm

          -  History of hypersensitivity to Mucinex®

          -  Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical
             steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Dana, M.D, MPH, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ophthalmology Clinical Research</last_name>
    <phone>617-573-6060</phone>
    <email>opthalmologyclinicalresearch@meei.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijeeta Tadla</last_name>
      <phone>617-573-6060</phone>
      <email>opthalmologyclinicalresearch@meei.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Dana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Reza Dana, MD</investigator_full_name>
    <investigator_title>Reza Dana, MD, MPH, MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

